Cessation or persistence of embolic signals after antithrombotic treatment in characteristics of patients positive for embolic signals at entry
| Cessation of embolic signals | Persistence of embolic signals | p Value | |
|---|---|---|---|
| Values are frequency (%) unless otherwise stated. ASA, acetylsalicylic acid; TCD, transcranial Doppler. | |||
| Patients | 19 (100) | 25 (100) | |
| Sex, male | 11 (58) | 17 (68) | 0.71 |
| Age (y (mean (SD))) | 56.3 (11) | 61.6 (15) | 0.063 |
| Hypertension | 9 (47) | 16 (64) | 0.42 |
| Diabetes | 3 (16) | 6 (24) | 0.71 |
| Hypercholesterolaemia | 5 (26) | 9 (36) | 0.72 |
| Smoker | 9 (47) | 6 (24) | 0.071 |
| Hemispheric (non-ocular) symptoms | 18 (95) | 20 (80) | 0.21 |
| Persistent (non-transient) symptoms | 11 (58) | 14 (56) | 1.00 |
| Recurrent initial ischaemic events | 12 (63) | 13 (52) | 0.67 |
| Preexisting ASA prevention | 6 (32) | 5 (20) | 0.49 |
| Subcortical infarction≤15 mm | 5 (26) | 7 (28) | 0.98 |
| Territorial infarction | 9 (47) | 11 (44) | 0.98 |
| Extracranial stenosis (non-intracranial) | 12 (63) | 19 (76) | 0.55 |
| High grade stenosis (non-medium-grade) | 12 (63) | 17 (68) | 0.99 |
| Ischaemia to 1st TCD (days (mean (range))) | 5.3 (0.3–17.4) | 5.4 (0.3–21.6) | 0.86 |
| Embolic signals/h at 1st TCD (mean (range)) | 12.1 (1–29) | 17.2 (1–57) | 0.74 |
| 1st TCD to treatment (h (mean (range))) | 5.6 (1.0–46.5) | 2.4 (1.0–11.7) | 0.83 |
| Treatment to 2nd TCD (days (mean (range))) | 1.9 (0.02–3.9) | 1.7 (0.02–3.9) | 0.40 |